Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | PSMB1 | P20618 | 2/20 | 0.41 |
| ▸ | PSMB5 | P28074 | 2/20 | 0.41 |
| ▸ | PSMB2 | P49721 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 9/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | MAOB | P27338 | 5/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13475860 | 0.92 | SMN1; SMN2 (0.53) | KDM4EPSMB1PSMB5PSMB2SMN1; SMN2 | |
| SCHEMBL2471818 | 0.89 | SMN1; SMN2 (0.50) | KDM4EPSMB1PSMB5PSMB2SMN1; SMN2 | |
| SCHEMBL11789508 | 0.89 | KDM4E (0.49) | KDM4ESMN1; SMN2CYP3A4HRH3ALDH1A1 | |
| SCHEMBL1506584 | 0.85 | SMN1; SMN2 (0.46) | KDM4EPSMB1PSMB5PSMB2SMN1; SMN2 | |
| SCHEMBL419937 | 0.84 | THRB (0.41) | KDM4EALDH1A1 | |
| SCHEMBL12136354 | 0.81 | SMN1; SMN2 (0.47) | KDM4EPSMB1PSMB5PSMB2SMN1; SMN2 | |
| SCHEMBL13018291 | 0.81 | KDM4E (0.42) | KDM4ESMN1; SMN2CYP3A4HRH3ALDH1A1 | |
| SCHEMBL9634995 | 0.81 | KDM4E (0.41) | KDM4EPSMB1PSMB5PSMB2SMN1; SMN2 | |
| SCHEMBL720020 | 0.79 | DRD2 (0.48) | KDM4EMEN1KMT2A | |
| SCHEMBL11788154 | 0.79 | SMN1; SMN2 (0.47) | KDM4ESMN1; SMN2CYP3A4ALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 144 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2524947-B1 | ORGANIC PASSIVATION LAYER COMPOSITION, TRANSISTOR AND/OR ELECTRONIC DEVICE INCLUDING ORGANIC PASSIVATION LAYER FABRICATED THEREFROM | SAMSUNG ELECTRONICS CO LTD (KR) | 2017-07-12 | — | — | EP | claimed |
| US-9023980-B2 | Organic passivation layer composition, transistor and/or electronic device including organic passivation layer fabricated therefrom | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2015-05-05 | — | — | US | claimed |
| EP-1099983-B1 | Chemically amplified positive resist composition and patterning method | SHINETSU CHEMICAL CO (JP) | 2014-08-06 | — | — | EP | claimed |
| EP-2575188-B1 | Organic insulator composition including a hydroxyl group-containing polymer, dielectric film and organic thin film transistor using the same | SAMSUNG ELECTRONICS CO LTD (KR) | 2014-05-21 | — | — | EP | claimed |
| EP-2575188-A2 | Organic insulator composition including a hydroxyl group-containing polymer, dielectric film and organic thin film transistor using the same | Samsung Electronics Co., Ltd (KR) | 2013-04-03 | — | — | EP | claimed |
| US-20120291857-A1 | Organic Passivation Layer Composition, Transistor And/Or Electronic Device Including Organic Passivation Layer Fabricated Therefrom | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2012-11-22 | — | — | US | claimed |
| EP-2524947-A1 | Organic passivation layer composition, transistor and/or electronic device including organic passivation layer fabricated therefrom | Samsung Electronics Co., Ltd. (KR) | 2012-11-21 | — | — | EP | claimed |
| US-8003729-B2 | comprising crosslinkable polyvinylalcohol, polyvinylphenol, polyhydroxyphenylmaleimide, aromatic polyimides and crosslinking agent; resist to heat and chemical; organic thin film transistor | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2011-08-23 | — | — | US | claimed |
| US-20100222393-A1 | MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES LIMITED (IN) | 2010-09-02 | — | — | US | claimed |
| US-20100004215-A1 | COMPOSITIONS OF PHOSPHODIESTERASE TYPE IV INHIBITORS | RANBAXY LABORATORIES LIMITED (IN) | 2010-01-07 | — | — | US | claimed |
| EP-2111861-A1 | Compositions of phosphodiesterase type IV inhibitors | Ranbaxy Laboratories Limited (IN) | 2009-10-28 | — | — | EP | claimed |
| EP-1995799-A2 | Organic insulator composition including a hydroxyl group-containing polymer, dielectric film and organic thin film transistor using the same | Samsung Electronics Co., Ltd. (KR) | 2008-11-26 | — | — | EP | claimed |
| US-20080283829-A1 | Organic insulator composition including a hydroxyl group-containing polymer, dielectric film and organic thin film transistor using the same | SAMSUNG ELECTRONICS CO., LTD. | 2008-11-20 | — | — | US | claimed |
| US-20250289960-A1 | MATERIAL KIT, CURABLE COMPOSITION, FILM FORMING METHOD, AND ARTICLE MANUFACTURING METHOD | CANON KABUSHIKI KAISHA (JP) | 2025-09-18 | — | — | US | disclosed |
| US-20240416578-A1 | LAYER FORMING COMPOSITION, FILM FORMING METHOD, AND ARTICLE MANUFACTURING METHOD | CANON KABUSHIKI KAISHA (JP) | 2024-12-19 | — | — | US | disclosed |
| US-20230350302-A1 | POLYMER CROSSLINK DE-CROSSLINK PROCESSES FOR RESIST PATTERNING | TAIWAN SEMICONDUCTOR MANUFACTURING COMPANY, LTD. (TW) | 2023-11-02 | — | — | US | disclosed |
| EP-1033624-A1 | RADIATION-SENSITIVE COMPOSITION OF CHEMICAL AMPLIFICATION TYPE | Clariant International Ltd. (CH) | 2000-09-06 | — | — | EP | disclosed |
| EP-0464408-B1 | Process for preparing star compounds | SEKISUI CHEMICAL CO LTD (JP) | 1994-01-12 | — | — | EP | disclosed |
| US-5102966-A | Addition polymerization of unsaturated ethers using an unsaturated alkenyl polyether adduct as initiator and a cation-donating compound | SEKISUI CHEMICAL CO., LTD. (JP) | 1992-04-07 | — | — | US | disclosed |
| EP-0464408-A1 | Process for preparing star compounds | SEKISUI CHEMICAL CO., LTD. (JP) | 1992-01-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100222393-A1 | MUSCARINIC RECEPTOR ANTAGONISTS | CHRM3, CHRM2, CHRM1 | KDM4E 4123/4885PSMB1 2393/4885PSMB5 2553/4885 |
| US-20100004215-A1 | COMPOSITIONS OF PHOSPHODIESTERASE TYPE IV INHIBITORS | PDE4B, PDE4A, PDE3B | KDM4E 1748/4885PSMB1 1263/4885PSMB5 845/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.